EP4412595A1 - A tablet comprising micronized brexpiprazole - Google Patents

A tablet comprising micronized brexpiprazole

Info

Publication number
EP4412595A1
EP4412595A1 EP22879046.5A EP22879046A EP4412595A1 EP 4412595 A1 EP4412595 A1 EP 4412595A1 EP 22879046 A EP22879046 A EP 22879046A EP 4412595 A1 EP4412595 A1 EP 4412595A1
Authority
EP
European Patent Office
Prior art keywords
sodium
film coated
coated tablet
tablet according
brexpiprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22879046.5A
Other languages
German (de)
French (fr)
Other versions
EP4412595A4 (en
Inventor
Mustafa MARASLI
Arzu PALANTOKEN
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority claimed from PCT/TR2022/051075 external-priority patent/WO2023059296A1/en
Publication of EP4412595A1 publication Critical patent/EP4412595A1/en
Publication of EP4412595A4 publication Critical patent/EP4412595A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Definitions

  • the present invention relates to a film coated tablet comprises micronized brexpiprazole or a salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
  • Brexpiprazole acts as a partial agonist of the serotonin 5-HT1A receptor and the dopamine D2 and D3 receptors. Brexpiprazole has been described for use in the treatment of schizophrenia, depression and other central nervous system disorders, and for use in the prophylaxis and/or treatment of behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease.
  • Brexpiprazole is a compound represented by the following Formula I, and its chemical name is 7-[4-[4-(1 -benzothiophen-4-yl)piperazin-1 -yl]butoxy]-1 H-quinolin-2-one.
  • Brexpiprazole is an antidepressant and antipsychotic drug marketed under the brand Rexulti® for the oral treatment of schizophrenia and as an adjunctive treatment to antidepressants in major depressive disorder.
  • REXULTI tablets are intended for oral administration and available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths. The product was approved in the U.S. in 2015 for the aforementioned indications and is currently in phase III trials for the treatment of agitation associated with Alzheimer's disease and the treatment of PTSD (post-traumatic stress disorder).
  • Brexpiprazole has poor solubility in water.
  • the major limitation of the drug is its low solubility and permeability leading to poor bioavailability. So, in a formulation comprising brexpiprazole, solubility is important.
  • WO 2013/054872 patent application discloses pharmaceutical formulations comprising brexpiprazole and methods for their manufacture.
  • the document describes producing uncoated or coated tablets of brexpiprazole using the following components: brexpiprazole, lactose, corn starch, microcrystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose and magnesium stearate.
  • the compositions described therein are prepared by wet granulation techniques.
  • CN105412036 patent application discloses an orally disintegrating tablet containing Brexpiprazole where the improvement in dissolution is provided by the reduction of the active substance particle size below 10 pm in a course of co- grinding process utilizing lactose.
  • a film coated tablet comprising brexpiprazole or a salt thereof that provides a film coated tablet having the desired stability, dissolution profile, hardness and compressibility, in another words the disadvantages seen in the active substance will able to overcome.
  • the formulation has been developed by using standard techniques which is simple and cost-effective method.
  • the main object of the present invention is to eliminate problems caused by active substance, brexpiprazole, and bringing additional advantages to the relevant prior art.
  • Another object of the present invention is to provide a film coated tablet comprising brexpiprazole with high stability, having desired level of dissolution rate which overcomes the above described problems in prior art and have additive advantages over them.
  • Another object of the present invention is to provide a film coated tablet comprising brexpiprazole having improved content uniformity and compressibility.
  • particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis).
  • d (0.9) means the size at which %90 by volume of the particles are finer.
  • brexpiprazole or a salt thereof having the following particle sizes is very important for formulation. Especially, it positively affects the dissolution properties and powder homogenization.
  • the obtained film coated tablets have the desired dissolution profile.
  • the powder is more homogeneous.
  • the content uniformity of the film coated tablets obtained from the more homogeneous powder is more ideal. Therefore, it provides better bioavailability.
  • amount of disintegrant is between 0.1% and 25.0% by weight helps to provide the desired dissolution profile in the formulation.
  • a film coated tablet comprises brexpiprazole or a salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient wherein brexpiprazole or a salt thereof having particle size d90 less than about 50 microns and the amount of disintegrant in the tablet is 0.1% to 25.0% by weight.
  • brexpiprazole or a salt thereof has a d (0.9) particle size less than 45 pm, preferably less than 40 pm.
  • the amount of brexpiprazole or a salt thereof is between 0.1% and 10.0% by weight of the total composition.
  • excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation is developed.
  • the formulations should have no physicochemical incompatibility between the active agent and the excipients.
  • Suitable disintegrants are selected from the group comprising sodium starch glycolate, crospovidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, sodium alginate, corn starch, alginic acid, magnesium aluminium silica, poloxamer, sodium glycine carbonate or mixtures thereof.
  • the disintegrant is sodium starch glycolate.
  • sodium starch glycolate helps to provide the desired dissolution profile.
  • Sodium starch glycolate absorbs water rapidly, resulting in swelling which leads to rapid disintegration of tablets.
  • the amount of disintegrant in the tablet is 0.1% to 20.0% by weight, preferably 0.1% to 10.0% by weight of the total composition.
  • the pharmaceutically acceptable excipients are selected from the group comprising fillers, binders, lubricants, surfactants or mixtures thereof.
  • Suitable fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals, sulfobutylether betacyclodextrin, talc, tragacanth, trehalose, polysorbate 80, x
  • the filler is lactose monohydrate, microcrystalline cellulose, mannitol or pregelatinized starch or mixtures thereof.
  • the amount of filler in the tablet is 60.0% to 90.0% by weight of the total composition.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, corn starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, , polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
  • the binder is polyvinylpyrrolidone or carboxymethylcellulose sodium or mixtures thereof.
  • the amount of binder in the tablet is 0.1% to 20.0% by weight of the total composition. According to this embodiment of the present invention, the amount of binder in the tablet is 0.1% to 10.0% by weight of the total composition.
  • Suitable lubricants are selected from the group comprising sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate, talc, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium lauryl sulphate or mixtures thereof.
  • the lubricant is sodium stearyl fumarate. It improves the powder processing properties of film coated tablet formulation. Also, it enhances powder flow by reducing the inter-particle friction.
  • the amount of lubricant in the tablet is 0.1% to 5.0% by weight of the total composition.
  • a surfactant is a substance that is generally a compound which lowers the surface tension between two liquids or between a liquid and a solid.
  • Suitable surfactants are selected from the group comprising sodium lauryl sulphate, benzalconium chloride, docusate sodium, glyceryl esters, glyceryl monoleate, poloxamer, polyethylene alkyl ethers, polyglyceryl esters, polysorbates, polyoxyetylene esters, polyoxyetylene stearates, sodium stearate, hexadecyl pyridinium chloride or mixtures thereof.
  • the surfactant is sodium lauryl sulphate.
  • the amount of surfactant in the tablet is 0.1% to 10.0% by weight of the total composition.
  • a film coat on the tablet protects from moisture and further contributes to the ease with which it can be swallowed. Also, it is used in order to minimize for stability problems.
  • the film coated tablet of the present invention may prepared by direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying or solvent evaporation.
  • the film coated tablet is prepared wet granulation which is simple and cost-effective method. Also, this process helps to provide stability and dissolution profile of the film coated tablet.
  • Solvent is used in the process. Suitable solvents are selected from the group comprising water, ethanol, dichloromethane, 0.1 N HCI, methanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether, glycerol formal, propylene carbonate or mixtures thereof.
  • the solvent during wet granulation is water or ethanol or mixtures thereof.
  • the solvent during wet granulation is ethanokwater (50:50) mixture.
  • the film coated tablet is prepared by dry granulation- compaction which is simple and cost-effective method.
  • the film coated tablet comprises;
  • the film coated tablet comprises;
  • Example 1 The film coated tablet is prepared by wet granulation with water A process for example 1 ; a) Mixing brexpiprazole and 14 of lactose monohydrate by weight, b) Adding half of the remaining lactose monohydrate and mixing, c) Adding the remaining part of lactose monohydrate and mixing, d) Adding Microcrystalline cellulose and mixing, e) Adding sodium starch glycolate and polyvinylpyrrolidone and then mixing, f) Granulating the mixture with water, g) Sieving and then drying, h) Sieving the dried granules and adding sodium stearyl fumarate and then mixing, i) Compressing the total mixture into tablets j) Coating the tablets with film coating.
  • Example 2 The film coated tablet is prepared by wet granulation with water
  • a process for example 2 a) Mixing brexpiprazole and 14 of pregelatinized starch by weight, b) Adding half of the remaining pregelatinized starch and mixing, c) Adding the remaining part of pregelatinized starch and mixing, d) Adding mannitol and mixing, e) Adding sodium starch glycolate and polyvinylpyrrolidone and then mixing, f) Granulating the mixture with water, g) Sieving and then drying, h) Sieving the dried granules and adding sodium stearyl fumarate and then mixing, i) Compressing the total mixture into tablets j) Coating the tablets with film coating.
  • Example 3 The film coated tablet is prepared by wet granulation with water or ethanol-water mixture
  • a process for example 3 a) Mixing Lactose Monohydrate, Microcrystalline Cellulose, Sodium starch glycolate b) Dissolving carboxymethylcellulose sodium and sodium lauryl sulphate in water and then adding ethanol c) Adding brexpiprazole to step (b) and homogenizing the mixture, d) Granulating the mixture at step (a) with the mixture step (c), e) Sieving and then drying, f) Sieving the dried granules and adding sodium stearyl fumarate and then mixing, g) Compressing the total mixture into tablets h) Coating the tablets with film coating.
  • Example 4 The film coated tablet is prepared by dry granulation- compaction
  • a process for example 4 a) Mixing brexpiprazole, lactose monohydrate, mannitol, polyvinylpyrrolidone, sodium starch glycolate, b) Compacting the mixture at step (a), sieving and then mixing, c) Adding sodium stearyl fumarate and then mixing, d) Compressing the total mixture into tablets e) Coating the tablets with film coating.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a film coated tablet comprises micronized brexpiprazole or a salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.

Description

A TABLET COMPRISING MICRONIZED BREXPIPRAZOLE
Field of the Invention
The present invention relates to a film coated tablet comprises micronized brexpiprazole or a salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
Background of the Invention
Brexpiprazole acts as a partial agonist of the serotonin 5-HT1A receptor and the dopamine D2 and D3 receptors. Brexpiprazole has been described for use in the treatment of schizophrenia, depression and other central nervous system disorders, and for use in the prophylaxis and/or treatment of behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease.
Brexpiprazole is a compound represented by the following Formula I, and its chemical name is 7-[4-[4-(1 -benzothiophen-4-yl)piperazin-1 -yl]butoxy]-1 H-quinolin-2-one.
Brexpiprazole is an antidepressant and antipsychotic drug marketed under the brand Rexulti® for the oral treatment of schizophrenia and as an adjunctive treatment to antidepressants in major depressive disorder. REXULTI tablets are intended for oral administration and available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths. The product was approved in the U.S. in 2015 for the aforementioned indications and is currently in phase III trials for the treatment of agitation associated with Alzheimer's disease and the treatment of PTSD (post-traumatic stress disorder).
Brexpiprazole has poor solubility in water. The major limitation of the drug is its low solubility and permeability leading to poor bioavailability. So, in a formulation comprising brexpiprazole, solubility is important. WO 2013/054872 patent application discloses pharmaceutical formulations comprising brexpiprazole and methods for their manufacture. In particular, the document describes producing uncoated or coated tablets of brexpiprazole using the following components: brexpiprazole, lactose, corn starch, microcrystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose and magnesium stearate. The compositions described therein are prepared by wet granulation techniques.
CN105412036 patent application discloses an orally disintegrating tablet containing Brexpiprazole where the improvement in dissolution is provided by the reduction of the active substance particle size below 10 pm in a course of co- grinding process utilizing lactose.
In prior art, low solubility of brexpiprazole has been approached in several ways. However, these studies in the prior art have been it strongly affects the dissolution profile of pharmaceutical compositions comprising brexpiprazole, and therefore causes problems with the development of a pharmaceutical formulation with a specified dissolution profile, it is not the case that only the careful selection of excipients, binders, disintegrants and other ingredients customarily used in pharmaceutical compositions or reducing particle size of active agent is important for the development of a composition with favorable solubility characteristics.
There is thus still a need for a film coated tablet comprising brexpiprazole or a salt thereof that provides a film coated tablet having the desired stability, dissolution profile, hardness and compressibility, in another words the disadvantages seen in the active substance will able to overcome. The formulation has been developed by using standard techniques which is simple and cost-effective method.
Detailed Description of the Invention
The main object of the present invention is to eliminate problems caused by active substance, brexpiprazole, and bringing additional advantages to the relevant prior art.
Another object of the present invention is to provide a film coated tablet comprising brexpiprazole with high stability, having desired level of dissolution rate which overcomes the above described problems in prior art and have additive advantages over them.
Another object of the present invention is to provide a film coated tablet comprising brexpiprazole having improved content uniformity and compressibility.
As used here in, ‘particle size’ means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis). The term d (0.9) means the size at which %90 by volume of the particles are finer.
We have found that brexpiprazole or a salt thereof having the following particle sizes is very important for formulation. Especially, it positively affects the dissolution properties and powder homogenization. The obtained film coated tablets have the desired dissolution profile. The powder is more homogeneous. The content uniformity of the film coated tablets obtained from the more homogeneous powder is more ideal. Therefore, it provides better bioavailability. In addition to this having amount of disintegrant is between 0.1% and 25.0% by weight helps to provide the desired dissolution profile in the formulation.
According to one embodiment of the present invention, a film coated tablet comprises brexpiprazole or a salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient wherein brexpiprazole or a salt thereof having particle size d90 less than about 50 microns and the amount of disintegrant in the tablet is 0.1% to 25.0% by weight.
In one embodiment of the invention, brexpiprazole or a salt thereof has a d (0.9) particle size less than 45 pm, preferably less than 40 pm.
According to one embodiment of the present invention, the amount of brexpiprazole or a salt thereof is between 0.1% and 10.0% by weight of the total composition.
In general terms, excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation is developed. The formulations should have no physicochemical incompatibility between the active agent and the excipients.
Suitable disintegrants are selected from the group comprising sodium starch glycolate, crospovidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, sodium alginate, corn starch, alginic acid, magnesium aluminium silica, poloxamer, sodium glycine carbonate or mixtures thereof.
According to this embodiment of the present invention, the disintegrant is sodium starch glycolate. Especially, using sodium starch glycolate helps to provide the desired dissolution profile. Sodium starch glycolate absorbs water rapidly, resulting in swelling which leads to rapid disintegration of tablets.
According to this embodiment of the present invention, the amount of disintegrant in the tablet is 0.1% to 20.0% by weight, preferably 0.1% to 10.0% by weight of the total composition.
According to this embodiment of the present invention, the pharmaceutically acceptable excipients are selected from the group comprising fillers, binders, lubricants, surfactants or mixtures thereof.
Suitable fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals, sulfobutylether betacyclodextrin, talc, tragacanth, trehalose, polysorbate 80, xylitol or mixtures thereof.
According to this embodiment of the present invention, the filler is lactose monohydrate, microcrystalline cellulose, mannitol or pregelatinized starch or mixtures thereof.
According to this embodiment of the present invention, the amount of filler in the tablet is 60.0% to 90.0% by weight of the total composition.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, corn starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, , polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
According to this embodiment of the present invention, the binder is polyvinylpyrrolidone or carboxymethylcellulose sodium or mixtures thereof.
According to this embodiment of the present invention, the amount of binder in the tablet is 0.1% to 20.0% by weight of the total composition. According to this embodiment of the present invention, the amount of binder in the tablet is 0.1% to 10.0% by weight of the total composition.
Suitable lubricants are selected from the group comprising sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate, talc, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium lauryl sulphate or mixtures thereof.
According to this embodiment of the present invention, the lubricant is sodium stearyl fumarate. It improves the powder processing properties of film coated tablet formulation. Also, it enhances powder flow by reducing the inter-particle friction.
According to this embodiment of the present invention, the amount of lubricant in the tablet is 0.1% to 5.0% by weight of the total composition.
A surfactant is a substance that is generally a compound which lowers the surface tension between two liquids or between a liquid and a solid. Suitable surfactants are selected from the group comprising sodium lauryl sulphate, benzalconium chloride, docusate sodium, glyceryl esters, glyceryl monoleate, poloxamer, polyethylene alkyl ethers, polyglyceryl esters, polysorbates, polyoxyetylene esters, polyoxyetylene stearates, sodium stearate, hexadecyl pyridinium chloride or mixtures thereof.
According to this embodiment of the present invention, the surfactant is sodium lauryl sulphate.
According to this embodiment of the present invention, the amount of surfactant in the tablet is 0.1% to 10.0% by weight of the total composition.
In another embodiment of this present invention, a film coat on the tablet protects from moisture and further contributes to the ease with which it can be swallowed. Also, it is used in order to minimize for stability problems.
The film coated tablet of the present invention may prepared by direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying or solvent evaporation.
According to this embodiment of the present invention, the film coated tablet is prepared wet granulation which is simple and cost-effective method. Also, this process helps to provide stability and dissolution profile of the film coated tablet. Solvent is used in the process. Suitable solvents are selected from the group comprising water, ethanol, dichloromethane, 0.1 N HCI, methanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether, glycerol formal, propylene carbonate or mixtures thereof.
According to this embodiment of the present invention, the solvent during wet granulation is water or ethanol or mixtures thereof.
According to this embodiment of the present invention, the solvent during wet granulation is ethanokwater (50:50) mixture.
According to this embodiment of the present invention, the film coated tablet is prepared by dry granulation- compaction which is simple and cost-effective method.
According to this embodiment of the present invention, the film coated tablet comprises;
■ Brexpiprazole or a salt thereof having particle size d90 less than about 50 microns,
■ 0.1-25.0% by weight of sodium starch glycolate
■ 0.1 -5.0% by weight of lubricants of the total composition.
According to this embodiment of the present invention, the film coated tablet comprises;
■ Brexpiprazole or a salt thereof having particle size d90 less than about 50 microns,
■ Sodium starch glycolate
■ Sodium stearyl fumarate
Example 1 : The film coated tablet is prepared by wet granulation with water A process for example 1 ; a) Mixing brexpiprazole and 14 of lactose monohydrate by weight, b) Adding half of the remaining lactose monohydrate and mixing, c) Adding the remaining part of lactose monohydrate and mixing, d) Adding Microcrystalline cellulose and mixing, e) Adding sodium starch glycolate and polyvinylpyrrolidone and then mixing, f) Granulating the mixture with water, g) Sieving and then drying, h) Sieving the dried granules and adding sodium stearyl fumarate and then mixing, i) Compressing the total mixture into tablets j) Coating the tablets with film coating.
Example 2: The film coated tablet is prepared by wet granulation with water
A process for example 2; a) Mixing brexpiprazole and 14 of pregelatinized starch by weight, b) Adding half of the remaining pregelatinized starch and mixing, c) Adding the remaining part of pregelatinized starch and mixing, d) Adding mannitol and mixing, e) Adding sodium starch glycolate and polyvinylpyrrolidone and then mixing, f) Granulating the mixture with water, g) Sieving and then drying, h) Sieving the dried granules and adding sodium stearyl fumarate and then mixing, i) Compressing the total mixture into tablets j) Coating the tablets with film coating. Example 3: The film coated tablet is prepared by wet granulation with water or ethanol-water mixture
A process for example 3; a) Mixing Lactose Monohydrate, Microcrystalline Cellulose, Sodium starch glycolate b) Dissolving carboxymethylcellulose sodium and sodium lauryl sulphate in water and then adding ethanol c) Adding brexpiprazole to step (b) and homogenizing the mixture, d) Granulating the mixture at step (a) with the mixture step (c), e) Sieving and then drying, f) Sieving the dried granules and adding sodium stearyl fumarate and then mixing, g) Compressing the total mixture into tablets h) Coating the tablets with film coating.
Example 4: The film coated tablet is prepared by dry granulation- compaction
A process for example 4; a) Mixing brexpiprazole, lactose monohydrate, mannitol, polyvinylpyrrolidone, sodium starch glycolate, b) Compacting the mixture at step (a), sieving and then mixing, c) Adding sodium stearyl fumarate and then mixing, d) Compressing the total mixture into tablets e) Coating the tablets with film coating.

Claims

CLAIMS A film coated tablet comprising brexpiprazole or a salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient wherein brexpiprazole or a salt thereof having particle size d90 less than about 50 microns and the amount of disintegrant in the tablet is 0.1% to 25.0% by weight. The film coated tablet according to claim 1 , wherein disintegrants are selected from the group comprising sodium starch glycolate, crospovidone, cross-linked carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, sodium alginate, corn starch, alginic acid, magnesium aluminium silica, poloxamer, sodium glycine carbonate or mixtures thereof. The film coated tablet according to any preceding claim, wherein disintegrant is sodium starch glycolate. The film coated tablet according to any preceding claim, wherein amount of disintegrant in the tablet is 0.1% to 20.0% by weight, preferably 0.1% to 10.0% by weight of the total composition. The film coated tablet according to claim 1 , wherein the pharmaceutically acceptable excipients are selected from the group comprising fillers, binders, lubricants, surfactants or mixtures thereof. The film coated tablet according to claim 5, wherein fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, polysorbate 80, xylitol or mixtures thereof. The film coated tablet according to any preceding claim, wherein the filler is lactose monohydrate, microcrystalline cellulose, mannitol or pregelatinized starch or mixtures thereof.
8. The film coated tablet according to claim 5, wherein binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, corn starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, , polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
9. The film coated tablet according to any preceding claim, wherein the binder is polyvinylpyrrolidone or carboxymethylcellulose sodium or mixtures thereof.
10. The film coated tablet according to claim 5, wherein lubricants are selected from the group comprising sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate, talc, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium lauryl sulphate or mixtures thereof.
11 . The film coated tablet according to claim any preceding claim, wherein the lubricant is sodium stearyl fumarate.
12. The film coated tablet according to claim 5, wherein surfactants are selected from the group comprising sodium lauryl sulphate, benzalconium chloride, docusate sodium, glyceryl esters, glyceryl monoleate, poloxamer, polyethylene alkyl ethers, polyglyceryl esters, polysorbates, polyoxyetylene esters, polyoxyetylene stearates, sodium stearate, hexadecyl pyridinium chloride or mixtures thereof.
13. The film coated tablet according to any preceding claim, wherein the surfactant is sodium lauryl sulphate.
14. The film coated tablet according to claim 1 , wherein the tablet comprising;
- Brexpiprazole or a salt thereof having particle size d90 less than about 50 microns,
- 0.1-25.0% by weight of sodium starch glycolate
- 0.1 -5.0% by weight of lubricants of the total composition.
15. The film coated tablet according to claim 5, wherein the tablet comprising;
- Brexpiprazole or a salt thereof having particle size d90 less than about 50 microns,
- Sodium starch glycolate
- Sodium stearyl fumarate
EP22879046.5A 2021-10-05 2022-10-03 TABLET WITH MICRONIZED BREXPIPRAZOLE Pending EP4412595A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR202101551 2021-10-05
PCT/TR2022/051075 WO2023059296A1 (en) 2021-10-05 2022-10-03 A tablet comprising micronized brexpiprazole

Publications (2)

Publication Number Publication Date
EP4412595A1 true EP4412595A1 (en) 2024-08-14
EP4412595A4 EP4412595A4 (en) 2025-10-15

Family

ID=91934291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22879046.5A Pending EP4412595A4 (en) 2021-10-05 2022-10-03 TABLET WITH MICRONIZED BREXPIPRAZOLE

Country Status (1)

Country Link
EP (1) EP4412595A4 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123300B2 (en) * 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
EP3501506B1 (en) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
US20200171025A1 (en) * 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof

Also Published As

Publication number Publication date
EP4412595A4 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
EP2442799B1 (en) Solid pharmaceutical composition comprising rivaroxaban
US20190125725A1 (en) Pharmaceutical compositions comprising brivaracetam
US20050008691A1 (en) Bicalutamide compositions
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
WO2022146354A1 (en) A film coated tablet comprising teriflunomide
WO2023059296A1 (en) A tablet comprising micronized brexpiprazole
WO2017170858A1 (en) Oral preparation having exceptional elutability
CA2966517C (en) Solid oral formulation of fenretinide
EP4412595A1 (en) A tablet comprising micronized brexpiprazole
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
EP4374856A1 (en) A process for tablets comprising brexpiprazole
WO2025136342A1 (en) Tablets comprising brexpiprazole
EP4574135A1 (en) Tablets comprising brexpiprazole
WO2026095901A1 (en) Tablet composition comprising brexpiprazole or a salt thereof
WO2025136341A1 (en) A tablet comprising brexpiprazole
EP4736846A1 (en) Tablet composition comprising brexpiprazole or a salt thereof
EP4574134A1 (en) A tablet comprising brexpiprazole
JP5448844B2 (en) Solid pharmaceutical composition comprising nebivolol
TR2022017701A1 (en) A PROCESS FOR TABLETS CONTAINING BREXPIPRAZole
WO2024112298A1 (en) A tablet comprising teriflunomide
WO2026059525A1 (en) A solid oral composition comprising cariprazine hydrochloride
WO2025071531A1 (en) A tablet formulation of lurasidone hydrochloride
EP4382097A1 (en) A tablet comprising teriflunomide
EP4442254A1 (en) Film coated tablets comprising empagliflozin
WO2025229513A1 (en) Pharmaceutical composition of resmetirom and process thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_58610/2024

Effective date: 20241026

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET A.S.

A4 Supplementary search report drawn up and despatched

Effective date: 20250911

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101AFI20250905BHEP

Ipc: A61K 31/496 20060101ALI20250905BHEP

Ipc: A61P 25/18 20060101ALI20250905BHEP

Ipc: A61K 9/28 20060101ALN20250905BHEP